Issue 3/2012

  • Are released GM mosquitos safe?

    In this issue:

    • Novartis poised to enter HCV market with Enanta compound
    • Norway to use sequencing data in the country’s healthcare system
    • Oxford Nanopore shakes up Next-Gen sequencing market
    • BIO-Europe Spring: Antibodies – Unlocking new markets
    • Spain leads EU project for iPSCs in cell replacement therapies
    • Bioton joins forces with Actavis to develop biosimilar insulins
    • European Commission presents 2020 roadmap to bioeconomy

Volume 2016

Volume 2015

Volume 2014

Volume 2013

Volume 2012

© 2007-2016 BIOCOM

http://www.european-biotechnology-news.com/magazine/ebsin/2012/3/pos/1.html?sort=desc&cHash=f5f2e5fdbfbf799a701ac9c5e77ce04b

Kurszettel

Alle Kurse

TOP

  • NEWRON (CH)22.65 CHF9.69%
  • VERNALIS (UK)45.00 GBP4.65%
  • KARO BIO (S)40.00 SEK4.44%

FLOP

  • PROTHENA PLC (IE)50.02 USD-7.70%
  • FLAMEL TECHNOLOGIES (F)13.85 USD-6.98%
  • BIONOR PHARMA (N)0.44 NOK-6.38%

TOP

  • DIAMYD MEDICAL -B- (S)7.25 SEK68.6%
  • KARO BIO (S)40.00 SEK34.2%
  • NEWRON (CH)22.65 CHF33.6%

FLOP

  • BIONOR PHARMA (N)0.44 NOK-27.9%
  • NOVOZYMES (DK)284.40 DKK-14.0%
  • RENEURON (UK)2.75 GBP-12.7%

TOP

  • KARO BIO (S)40.00 SEK2497.4%
  • NICOX (F)10.26 EUR451.6%
  • SAREUM HOLDINGS (UK)0.74 GBP252.4%

FLOP

  • BB BIOTECH (D)46.74 EUR-81.7%
  • EVOCUTIS (UK)0.04 GBP-78.9%
  • NEUROVIVE PHARMACEUTICAL AB (S)5.50 SEK-71.4%

No liability assumed, Date: 24.08.2016